Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors

  • 60 Accesses

  • 12 Citations

Summary

The effect of the combined administration of verapamil (i.p. twice daily) and doxorubicin (i.v once weekly) was tested in mice bearing the following: (a) a tumor with induced resistance to doxorubicin (B16VDXR melanoma line); (b) a tumor inherently resistant (MXT mammary carcinoma); and (c) four solid tumors sensitive to doxorubicin (B16 melanoma, B16V melanoma line, M5076 reticulum cell sarcoma, and Lewis lung carcinoma). Verapamil, given according to this treatment schedule, reached peak plasma concentrations of 3 μM. Such treatment did not enhance doxorubicin activity on either inherently or induced resistant tumors, whereas it significantly enhanced doxorubicin growth inhibition in all the sensitive tumors except the Lewis lung carcinoma. Doxorubicin pharmacokinetics after administration of the drug alone and in combination with verapamil was analyzed after the first and repeated treatments in animals bearing B16 melanoma or its resistant subline B16VDXR. The resistance of the B16VDXR line was associated with the ability of the tumor to retain less doxorubicin (AUC=83 μg h/g) than the sensitive tumor B16 (AUC=204 μg h/g) in spite of similar initial levels. The potentiating effect of doxorubicin activity by, verapamil in B16 melanoma was not associated with increased doxorubicin levels or retention in the tumor, nor were differences in doxorubicin levels or retention found in the B16VDXR line. The combined treatment did not modify doxorubicin pharmacokinetics in plasma, heart, or spleen. These studies suggest that verapamil in vivo is ineffective in potentiating doxorubicin activity in tumors against which doxorubicin is inactive, that sensitive tumors are heterogeneous in their sensitivity to modulation by verapamil, and that this effect is not associated with modification of doxorubicin pharmacokinetics.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Andersson B, Beran M, McCredie KB, Mavlight GM (1985) Clinical resistance and sensitivity to chemotherapy in human acute leukemia: in vitro correlation with drug uptake and lack of potentiation by verapamil. Proc Am Assoc Cancer Res 26: 347

  2. 2.

    Benson AB III, Trump DL, Koeller JM, Egorin MI, Olman EA, Witte RS, Davis TE, Tormey DC (1985) Phase I study of vinblastine and verapamil given by concurrent iv infusion. Cancer Treat Rep 69: 795

  3. 3.

    Chang BK, Gregory JA (1985) Comparison of the cellular pharmacology of doxorubicin in resistant and sensitive models of pancreatic cancer. Cancer Chemother Pharmacol 14: 132

  4. 4.

    Chauffer B, Martin F, Crignard A, Jeannin JF, Leclerc A (1984) Cytofluorescence localization of adriamycin in resistant colon cancer cells. Cancer Chemother Pharmacol 13: 14

  5. 5.

    Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP, Schabel FM Jr (1984) Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 44: 717

  6. 6.

    Danø K (1983) Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim. Biophys Acta 323: 466

  7. 7.

    Formelli F, Rossi C, Carsana R, Supino R, Parmiani G (1985) In vivo studies of a doxorubicin (DX) resistant line of melanoma B16. Proc Am Assoc Cancer Res 26: 344

  8. 8.

    Formelli F, Rossi C, Supino R, Parmiani G (1986a) In vivo characterization of a doxorubicin resistant B16 melanoma, cell line. Br J Cancer 54: 223–233

  9. 9.

    Formelli F, Carsana R, Pollini C (1986b) Comparative pharmacokinetics and metabolism of doxorubicin and 4-demethoxy-4′-0-methyldoxorubicin in tumor-bearing mice. Cancer Chemother Pharmacol 16: 15

  10. 10.

    Ganapathi R, Grazbowski D, Turnic R, Valenzuela R (1984) Correlation between potency of calmodulin inhibitors and effects on cellular levels and cytotoxic activity of doxorubicin (adriamycin) in resistant P388 mouse leukemia cells. Eur J Cancer Clin Oncol 20: 799

  11. 11.

    Gasic GJ, Gasic TB, Galanti N, Johnson T, Murphy S (1973) The role of platelets in the spread of malignant disease. Int J Cancer 11: 704

  12. 12.

    GeranRI, GreenbergNH, MacdonaldMM, Schumacher AM, AbbotBJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems (third edition). Cancer Chemother Rep 3: 2

  13. 13.

    Giavazzi R, Scholar E, Hart R (1983) Isolation and preliminary characterization of an adriamycin-resistant murine fibrosarcoma cell line. Cancer Res 43: 2216

  14. 14.

    Gordon S, Witul M, Cohen H, Sciandra J, Williams P, Gastpar H, Murphy GP, Ambrus JL (1979) Studies on platelet aggregation inhibitors in vivo: VIII. Effect, of pentoxifillyn on spontaneous tumor metastases. J Med 10: 435

  15. 15.

    Harapat SR, Kates RE (1980) High-performance liquid chromatographic analysis of verapamil: II. Simultaneous quantitation of verapamil and its active metabolite, norverapamil. J Chromatogr 181: 484

  16. 16.

    Hilgard P, Heller H, Schmidt CG (1976) The influence of platelet aggregation inhibitors on metastasis formation in mice. Z Krebsforsch 86: 243

  17. 17.

    Honn KV, Cicone B, Skoff A (1981) Prostacyclin: a potent antimetastatic agent. Science 212: 1270

  18. 18.

    Inaba M, Kobayashi H, Sakurai Y, Johnson RK (1979) Active efflux, of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res 39: 2200

  19. 19.

    Karpatkin S, Ambrogio C, Pearlstein E (1984) Lack of effect of in vivo prostacyclin on the development of pulmonary metastases in mice following intravenous injection of CT26 Colon Carcinoma Lewis lung carcinoma, or B16 amelanotic melanoma cells. Cancer. Res 44: 3880

  20. 20.

    Kolenich JJ, Mansur EG, Flynn A (1972) Haematological effects of aspirin (letter). Lancet 2: 714

  21. 21.

    Lampidis TJ, Munck JN, Krishan A, Tapiero H (1985) Reversal of resistance to rhodamine 123 in adriamycin resistant Friend leukemia cells. Cancer Res 45: 2626

  22. 22.

    Presant CA, Kennedy P, Wisemar C, Gala K, Wyres M (1984) Verapamil (V) plus adriamycin (A) — a phase I–II clinical study. Proc Am Soc Clin Oncol 3: 32

  23. 23.

    Rogan AM, Hamilton TC, Young RC (1984) Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994

  24. 24.

    Sigman LM, Egorin MJ, Cohen BE, Thompson BW (1986) In vivo evaluation of adriamycin (Adr) and continuous verapamil (V) infusion against murine P388 leukemia. Proc Am Assoc Cancer Res 27: 392

  25. 25.

    Stephens LC, Wang YM (1985) Adriamycin cardiotoxicity in rabbits treated with verapamil. Proc Am Assoc Cancer Res 26: 218

  26. 26.

    Supino R, Prosperi E, Formelli F, Mariani M, Parmiani G (1986) Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention. Br J Cancer 54: 33

  27. 27.

    Tsuruo T (1983) Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. Cancer Treat Rep 67: 889

  28. 28.

    Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967

  29. 29.

    Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1982) Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42: 4730

  30. 30.

    Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1983a) Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res 43: 2267

  31. 31.

    Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y (1983b) Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res 43: 2905

  32. 32.

    Tsuruo T, Iida H, Makishima F, Yamori T, Kawaba H, Tsukagoshi S, Sakurai Y (1985) Inhibition of spontaneous and experimental tumor metastasis by the calcium antagonist verapamil. Cancer Chemother Pharmacol 14: 30

  33. 33.

    Watson CS, Medina D, Clark JH (1979) Characterization and estrogen stimulation of cytoplasmic progesterone receptor in the ovarian-dependent MXT-3590 mammary tumor line. Cancer Res 39: 4098

  34. 34.

    Wood S Jr, Hilgard P (1972) Aspirin and tumor metastases. Lancet 2: 1416

  35. 35.

    Yanovic S, Preston L (1984) Effects of verapamil on daunomycin cellular retention and cytotoxicity in P388 leukemic cells. Cancer Res 44: 1743

Download references

Author information

Correspondence to Franca Formelli.

Additional information

This work was supported by grant no. 84.00855.44 of the Finalized Project “Oncologia” from the Consiglio Nazionale delle Ricerche, Rome

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Formelli, F., Cleris, L. & Carsana, R. Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors. Cancer Chemother. Pharmacol. 21, 329–336 (1988). https://doi.org/10.1007/BF00264200

Download citation

Keywords

  • Melanoma
  • Sarcoma
  • Doxorubicin
  • Verapamil
  • Peak Plasma Concentration